Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Expert Comments:

With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia.
read more >
Jason McCarthy, Maxim Group (10/16/17)
"Inovio Pharmaceuticals Inc. announced the initiation of a Phase 1b/2 study bladder cancer evaluating the triple combination of INO-5401 (multi-antigen immunotherapy) + INO-9012 (DNA-based IL-12) + Tecentriq (PD-L1). The collaboration was announced in June 2017 whereby Roche will supply Tecentriq for the study. . .Inovio continues to advance multiple early-stage studies forward which should provide incremental catalysts as data emerges. Our focus though remains on VGX-3100, which is in a pivotal trial in cervical dysplasia."

Ram Selvaraju, H.C. Wainwright & Co. (10/6/17)
"Inovio Pharmaceuticals Inc. announced that results from its first Phase 1 trial of DNA-based Zika vaccine (GLS-5700) had been published in the New England Journal of Medicine. . .GLS-5700 induced high levels of binding antibodies in all participants after a three-dose vaccination regimen at 14 weeks. . .these results demonstrate GLS-5700's potential efficacy in preventing Zika virus infection in human together with a solid safety profile, and bode well for the potential data readout from the second human trial around mid-2018. . .in the wake of this update, we reiterate our Buy rating and $13 price target.

H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer.
read more >
Ram Selvaraju, H.C. Wainwright & Co. (9/22/17)
"Inovio Pharmaceuticals Inc. announced the publication of two preclinical studies of the company's plasmid DNA-encoded monoclonal antibody (dMAb) constructs in treating cancer and preventing infection from a pneumonia-causing bacteria. . .in the wake of this update, we reiterate our Buy rating and $13 price target. . .the anti-cancer dMAb products work by binding the antigens on the cancer cells and killing them by an antibody dependent cytotoxicity mechanism in conjunction with natural killer cells. . .these novel mechanisms could provide multiple shots on goal and warrant potential future use of dMAb products in combination with other therapeutics."

Jason McCarthy, Maxim Group (9/12/17)
"Inovio Pharmaceuticals Inc. announced positive (Phase 1b) data for INO-5150 demonstrating immune responses against prostate specific antigen (PSA) and prostate specific membrane antigen in patients with biochemically (rising PSA) recurrent prostate cancer. . .the data thus far demonstrated immune responses in 60% of patients, including a portion of patients experiencing reduced PSA levels."

Ram Selvaraju, H.C. Wainwright & Co. (9/12/17)
"Inovio Pharmaceuticals Inc. presented data from an interim analysis of the Phase 1b trial of its INO-5150 cancer immunotherapy candidate in subjects with biochemically recurrent [rising prostate specific antigen (PSA)] prostate cancer. . .the results showed that INO-5150 generated PSA and prostate specific membrane antigen specific CD8+ killer T cell responses in peripheral blood in 60% (35/58) of the subjects. . .we view this as preliminary evidence that the company's immunotherapy may be used in a combination regimen to treat recurrent prostate cancer."

Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.
read more >
Zacks Equity Research (8/9/17)
"Inovio Pharmaceuticals Inc.'s VGX-3100, an HPV immunotherapy, is the most advanced candidate in the company's pipeline that is currently being developed for the treatment of HPV-16/18-related high-grade cervical dysplasia. Inovio initiated a phase III study to evaluate VGX-3100 for treatment of cervical dysplasia caused by human papillomavirus. . .during the same period, the company started a phase II study to examine the efficacy of VGX-3100 in women with HPV-related vulvar neoplasia."

A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018.
read more >
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors.
read more >
A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts.
read more >
J. Joseph Kim
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses.
read more >

More Expert Comments

Experts Following This Company

Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Nick Hodge, Founder and president of the Outsider Club – Outsider Club
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.